Engineered immune cells take on kidney cancer in first human test

NCT ID NCT07647744

Recruiting now Disease control Sponsor: Hrain Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This early-phase trial tests a new treatment for advanced kidney cancer that has spread. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The study will enroll 18 adults and focus on safety and finding the right dose, with a preliminary look at whether the treatment can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genetically modified immune cells (CAR T-cells) targeting CD70
What this could lead to: If this works, it could point toward a new treatment option for advanced kidney cancer that has stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 18 participants, so it is primarily testing safety. The treatment may not shrink tumors or may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nonpapillary renal cell carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA (RCC)

Contacts and locations

Locations

RenJi Hospital, Shanghai Jiaotong University School of Medicine
RECRUITING

Shanghai, 200000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.